霉酚酸酯治疗难治性炎症性眼病。
Mycophenolate Mofetil Therapy in Refractory Inflammatory Eye Disease.
作者信息
Cuchacovich Miguel, Solanes Federica, Perez Claudio, Verdaguer Juan Ignacio, Verdaguer Juan, Castiglione Enzo, Carpentier Cristian, Traipe Leonidas, Villarroel Francisco
机构信息
1 Department of Medicine, Clinical Hospital University of Chile , Santiago, Chile .
2 Ophthalmology Department, Clinical Hospital, Catholic University of Chile , Santiago, Chile .
出版信息
J Ocul Pharmacol Ther. 2016 Jan-Feb;32(1):55-61. doi: 10.1089/jop.2015.0044. Epub 2015 Nov 12.
PURPOSE
To study the efficacy and incidence of treatment-related side effects of mycophenolate mofetil (MMF) therapy in patients with noninfectious inflammatory eye diseases.
METHODS
Retrospective cohort study of 27 Chilean patients treated for noninfectious inflammatory eye diseases using MMF therapy over a 10-year period. Main outcome measures were: ability to control ocular inflammation and to taper prednisone to ≤10 mg daily (treatment success); incidence of treatment-related side effects.
RESULTS
The proportion of patients with sustained control of inflammation was 81.48% at 6 months. Additionally 55.56% and 22.22% of patients succeeded in tapering their prednisone to 5-10 mg/day and <5 mg/day, at 6 months. Two patients developed a neoplasia during MMF therapy; however, this cohort is too small to interpret the significance of this relation to MMF treatment.
CONCLUSIONS
MMF seems to be an effective corticosteroid-sparing agent with an acceptable safety profile.
目的
研究霉酚酸酯（MMF）治疗非感染性炎症性眼病的疗效及治疗相关副作用的发生率。
方法
对27例智利患者进行回顾性队列研究，这些患者在10年期间使用MMF治疗非感染性炎症性眼病。主要观察指标为：控制眼部炎症及将泼尼松减量至≤10毫克/日的能力（治疗成功）；治疗相关副作用的发生率。
结果
6个月时炎症得到持续控制的患者比例为81.48%。此外，6个月时分别有55.56%和22.22%的患者成功将泼尼松减量至5 - 10毫克/日和<5毫克/日。两名患者在MMF治疗期间发生肿瘤；然而，该队列规模太小，无法解读这种关联与MMF治疗的意义。
结论
MMF似乎是一种有效的皮质类固醇节省剂，安全性可接受。
Zotero 插件